Trial Profile
Immunogenicity And Safety Of An Alum-Adjuvanted Inactivated H7N9 Influenza Vaccine
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Apr 2020
Price :
$35
*
At a glance
- Drugs H7N9 influenza vaccine-Shanghai Institute Of Biological Products (Primary) ; Aluminium hydroxide
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions
- 20 Mar 2019 Planned End Date changed from 1 Dec 2019 to 29 Aug 2019.
- 09 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Jan 2019.